Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Cholesterol, lipids, and statins.

Ballantyne CM.

Tex Heart Inst J. 2005;32(3):378-9. Review.

2.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348
3.

Lipid management with statins. The lower the better?

Laufs U, Liao JK, Böhm M.

Z Kardiol. 2004 Jan;93(1):4-9. Review.

PMID:
14740235
4.

Newer HMG-CoA reductase inhibitor (statin) therapies.

Brinton EA.

Clin Cardiol. 2001;24(7 Suppl):II-10-3. Review.

5.

Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins.

Ferrières J.

Am J Cardiovasc Drugs. 2009;9(2):109-15. doi: 10.2165/00129784-200909020-00005. Review.

PMID:
19331439
6.

Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.

Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.

J Cardiovasc Pharmacol. 2008 Apr;51(4):331-51. doi: 10.1097/FJC.0b013e318165e2e7. Review.

PMID:
18427276
7.

Candidate mechanisms for regression of coronary atherosclerosis with high-dose statins: insight from intravascular ultrasonography trials.

Sipahi I, Tuzcu EM.

Am J Cardiovasc Drugs. 2008;8(6):365-71. doi: 10.2165/0129784-200808060-00003. Review.

PMID:
19159123
8.

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.

Daskalopoulou SS, Mikhailidis DP.

Curr Med Res Opin. 2006 Mar;22(3):511-28. Review.

PMID:
16574035
9.

[Treatment of the patient with ideal LDL cholesterol].

Mendoza Pérez E.

Arch Cardiol Mex. 2003 Apr-Jun;73 Suppl 1:S98-102. Review. Spanish.

PMID:
12966655
10.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Postgrad Med J. 2008 Nov;84(997):590-8. doi: 10.1136/hrt.2007.125401. Review.

PMID:
19103817
11.

Lipid-altering therapies and the progression of atherosclerotic disease.

Wierzbicki AS.

Cardiovasc Intervent Radiol. 2007 Mar-Apr;30(2):155-60. Review.

PMID:
17206389
12.

Residual risk in statin-treated patients: future therapeutic options.

Campbell CY, Rivera JJ, Blumenthal RS.

Curr Cardiol Rep. 2007 Nov;9(6):499-505. Review.

PMID:
17999876
13.

Total lipid management and residual risk: beyond statin therapy.

Evans M.

Br J Hosp Med (Lond). 2011 Mar;72(3):132-6. Review.

PMID:
21475092
14.

Mechanisms of disease: HDL metabolism as a target for novel therapies.

Rader DJ.

Nat Clin Pract Cardiovasc Med. 2007 Feb;4(2):102-9. Review.

PMID:
17245404
15.

A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.

Packard C.

Atheroscler Suppl. 2006 Apr;7(1):21-9. Epub 2006 Feb 28. Review.

PMID:
16504600
16.

Rationale for aggressive lipid lowering: evidence from clinical trials.

Farmer JA.

Expert Rev Cardiovasc Ther. 2004 May;2(3):305-9. Review. No abstract available.

PMID:
15151477
17.

Low-density lipoprotein cholesterol reduction: the end is more important than the means.

LaRosa JC.

Am J Cardiol. 2007 Jul 15;100(2):240-2. Epub 2007 May 24. Review.

PMID:
17631077
18.

Effect of lipid modification on progression of coronary calcification.

McCullough PA.

J Am Soc Nephrol. 2005 Nov;16 Suppl 2:S115-9. Review.

19.

Statins for stroke prevention.

Goldstein LB.

Curr Atheroscler Rep. 2007 Oct;9(4):305-11. Review.

PMID:
18173958
20.

[Intensive cholesterol lowering therapy to reduce cardiovascular risk].

Rigotti R A, Arteaga Ll A, Maiz G A.

Rev Med Chil. 2006 May;134(5):641-8. Epub 2006 Jun 19. Review. Spanish.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk